Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

CRISPR Therapeutics (Group)

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company’s scientific founder Emmanuelle Charpentier, Ph.D., who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. *

 

Period Start 2013-01-01 established
Product Industry CRISPR gene editing technology
Persons Person Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
  Person 2 Foy, Shaun P. (CRISPR Therapeutics 201404 CFO + Co-Founder + ERS Genomics CEO + Co-Founder before Nomura Phase4)
     
Region Region Basel BS
  Country Switzerland
  Street 36 Aeschenvorstadt
  City 4051 Basel
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency USD
  Annual sales 289,590,000 (revenue, collaboration, consolidated (2019) 2019-12-31)
  Profit 66,858,000 (2019-12-31)
  Cash 943,800,000 (2019-12-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2020-03-01

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC E Hand 650x300px




» top